Surgical resection of XXXX : The University of Iowa experience.

@entity1 @entity1358 @entity75 @entity3
The utility of surgical resection of solitary metastatic sites in @entity1358 remains controversial. Additionally, the small literature detailing the role of surgical management suggests that @entity1 who have surgical resection of metachronous @entity3 have a better outcome than those presenting synchronously. We reviewed the medical records of all @entity1 with @entity1358 who underwent nephrectomy at the University of Iowa Hospitals and Clinics between 1980 and 1993. @entity1 who had undergone surgical resection of metastatic disease, either at presentation or subsequent to their nephrectomy, were identified. Clinical parameters, time to treatment failure, and survival was evaluated. Eighteen @entity1 underwent surgical resection of @entity3 , 7 were synchronous to their nephrectomy, and 11 developed metachronous @entity3 . @entity75 in both groups included @entity3 to lung, bone, liver, brain, and soft tissue. The median survival of all @entity1 from time of resection to death or last follow-up was 5.7 years (range, 2 days to 10.7+ years). Two @entity1 remain alive, both with recurrent disease at 5.3 and 10.7 years. Mean time from nephrectomy to death was 2.69 years for the synchronous group and 5.97 years for the metachronous group (p = 0.0599). The role of surgical resection in @entity1358 remains unproven. The survival of this population is significantly longer than that typical for the disease. In our experience there is no difference in time to treatment failure or survival between synchronous and metachronous resection of metastatic disease.
